Anavex Life Sciences Corp (AVXL)

[F1ash]

“Dizziness was the most common adverse event (20 incidents in 15 patients), followed by headache (16 in 10 patients). Most (94%) occurred in the first week of treatment. All were mild or moderate. Headache and dizziness are considered signs that patients are approaching their maximum tolerated dose, Dr. Missling said.

The company’s task now is to find a standard minimum dose that is strong enough to get patients to at least 4 ng/mL plasma level, without inducing these side effects.


https://www.mdedge.com/neurology/article/152595/alzheimers-cognition/development-sigma-1-receptor-agonist-alzheimers